On February 23, the Securities and Exchange Commission issued a statement setting forth a “no-action” position regarding when substitutions by an insurance company of mutual funds held in a variable ...
Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar competition in the US. In 2009, Congress created a regulatory pathway for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results